NYSE: CPACCementos Pacasmayo Saa Stock
$7.27-0.03 (-0.41%)
Updated Oct 31, 2025
CPAC Price
$7.27
Fair Value Price
N/A
Market Cap
$622.47M
52 Week Low
$5.10
52 Week High
$7.50
P/E
9.67x
P/B
1.52x
P/S
1x
PEG
0.2x
Dividend Yield
7.46%
Revenue
$614.75M
Earnings
$63.82M
Gross Margin
37.6%
Operating Margin
20.2%
Profit Margin
10.7%
Debt to Equity
1.38
Operating Cash Flow
N/A
Beta
0.12
Next Earnings
N/A
Ex-Dividend
Nov 21, 2025
Next Dividend
Dec 18, 2025
CPAC Overview
Cementos Pacasmayo S.A.A. produces and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. It also produces and sells quicklime for use in mining operations. Cementos Pacasmayo S.A.A. operates as a subsidiary of Inversiones ASPI S.A. The company was incorporated in 1949 and is headquartered in Lima, Peru.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CPAC's potential to beat the market
- CPAC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Building Material
Industry Rating
D
CPAC
RankedUnranked of 14
RankedUnranked of 14
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.15 | B | |
| $117.22 | C | |
| $36.46 | C |
Be the first to know about important CPAC news, forecast changes, insider trades & much more!
CPAC News
Overview
Due Diligence Score
–
Industry Average (35)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CPAC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CPAC ($7.27) is trading below its intrinsic value of $17.96, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CPAC is good value based on its earnings relative to its share price (9.67x), compared to the US market average (41.56x)
P/E vs Market Valuation
CPAC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CPAC due diligence checks available for Premium users.
Valuation
CPAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.67x
Industry
25.37x
Market
41.56x
CPAC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CPAC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CPAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.52x
Industry
3.04x
CPAC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CPAC price to earnings growth (PEG)
For valuing profitable companies with growth potential
CPAC is good value based... subscribe to Premium to read more.
PEG Value Valuation
CPAC's financial health
Profit margin
Revenue
$165.0M
Net Income
$20.5M
Profit Margin
12.5%
CPAC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$946.1M
Liabilities
$548.2M
Debt to equity
1.38
CPAC's short-term assets ($341.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CPAC's short-term assets ($341.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CPAC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CPAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CPAC vs Building Material Stocks
Cementos Pacasmayo Saa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.